Non-Thermal Plasma Induces Antileukemic Effect Through mTOR Ubiquitination.

Cells
Sun-Yong KimChul-Ho Kim

Abstract

Non-thermal plasma (NTP) has been studied as a novel therapeutic tool for cancer that does not damage healthy cells. In this study, we show that NTP-treated solutions (NTS) can induce death in various leukemia cells through mechanistic target of rapamycin (mTOR) ubiquitination. Previously, we manufactured and demonstrated the efficacy of NTS in solid cancers. NTS did not exhibit any deleterious side effects, such as acute death or weight loss in nude mice. In the present study, NTS induced cell death in myeloid leukemia cells, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). We found that mTOR was downregulated in NTS-treated cells via the ubiquitin-proteasome system (UPS). We also identified 'really interesting new gene' finger protein 126 (RNF126) as a novel binding protein for mTOR through protein arrays and determined the role of E3 ligase in NTS-induced mTOR ubiquitination. NTS-derived reactive oxygen species (ROS) affected RNF126 expression and lysosomal dysfunction. These findings suggest that NTS has potential antileukemic effects through RNF126-mediated mTOR ubiquitination with no deleterious side effects. Thus, NTS may represent a new therapeutic method for chemotherapy-resistant leukemia.

References

Oct 6, 1998·Annual Review of Biochemistry·A Hershko, A Ciechanover
Jan 5, 2000·The EMBO Journal·J S ThrowerC M Pickart
Nov 23, 2000·Nature·R A DePinho
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Feb 13, 2002·Cell Death and Differentiation·M CastedoG Kroemer
Mar 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Joseph M DhahbiStephen R Spindler
Jun 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Zhaohui FengShengkan Jin
Oct 5, 2006·Cancer·Barbara Deschler, Michael Lübbert
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Sep 9, 2008·Biotechnology Advances·M MoreauM G J Feuilloley
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara RedaelliFrank Boschelli
May 20, 2009·Molecular Cell·Vladimir KirkinIvan Dikic
Oct 22, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander E PerlSelina M Luger
Nov 26, 2009·Cell Cycle·Jerome TamburiniDidier Bouscary
Jul 16, 2010·Applied Physics Letters·Chul-Ho KimSeung Joon Baek
Oct 15, 2010·Nature Reviews. Molecular Cell Biology·Jens TyedmersBernd Bukau
Oct 21, 2010·Journal of Biotechnology·Chul-Ho KimSeung Joon Baek
Jul 22, 2011·Nature·F Ulrich HartlManajit Hayer-Hartl
Sep 29, 2011·Cancer·Charles HardingRichard Wilson
Oct 8, 2011·British Journal of Cancer·M KeidarB Trink
May 25, 2012·The Journal of Clinical Investigation·Takayuki HoshiiAtsushi Hirao
Aug 28, 2012·Science·Gopa IyerDavid B Solit
Oct 25, 2012·Applied Physics Letters·Fengmin SuBohan Tian
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Jan 2, 2013·Proceedings of the National Academy of Sciences of the United States of America·Rebecca K DelkerF Nina Papavasiliou
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
PCR
Transfection
chip
Assay
chips
immunoprecipitation

Software Mentioned

R
GenePix Pro6
Affymetrix Command Console
MEV ( Multi Experiment Viewer )

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.